ClinicalTrials.gg
Not yet recruitingNCT07588698Updated Oct 1, 2026

Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma

A Phase 2 interventional study of Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP) and Epcoritamab in Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin and Diffuse Large B-Cell Lymphoma (DLBCL), sponsored by Carrie Ho, MD. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Primary conditionLymphoma, Large B-Cell, DiffuseRegistry: Lymphoma, B-CellReclassifiedWhy we changed it
Registry
Lymphoma, B-Cell — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Large B-Cell, Diffuse
Why
  1. The study's listed conditions name Lymphoma, Large B-Cell, Diffuse, a narrower term within Lymphoma, B-Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Carrie Ho, MD · Phase 2, Interventional, and Treatment

Updated Oct 1, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse — 16 open to participants now, 23 under way, 3 of them phase 3. epcoritamab · Lymphoma, Large B-Cell, Diffuse.

Planned enrollment
19th of 24
20 · median 41
Started
2026
with 6 others
Phase 2
14 of 24
12 open now
Primary completion
2028-08
later than 13 of 22 live
Registered
22nd of 24
by date
Lead sponsor
1 of 24
Carrie Ho, MD

Among the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse, this one is the 19th largest by planned enrollment, is one of 7 that started in 2026, is one of 14 in phase 2, reaches primary completion later than 13 of the 22 other live ones, and was the 22nd registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

16 of the 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse are open now, in 5 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About epcoritamab

epcoritamab: first FDA approval 2023 (EPKINLY), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing epcoritamab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

A Phase II, open-label, two-arm, multicenter study evaluating the combination of epcoritamab with R-CHOP chemotherapy in patients with newly diagnosed, aggressive B-cell non-Hodgkin lymphoma.

Read the detailed description

PRIMARY OBJECTIVES:

I. To evaluate the incidence and severity of all grade CRS cytokine release syndrome (CRS) in arm A and arm B.

SECONDARY OBJECTIVES:

I. To determine the safety and tolerability of the combination of epcoritamab and rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, prednisolone (R-CHOP) in both arms and individually.

II. The anti-tumor activity of epcoritamab + R-CHOP. III. To evaluate duration of response (DOR), progression-free survival (PFS), and overall survival (OS).

EXPLORATORY OBJECTIVES:

I. To evaluate changes in serum cytokine levels with epcoritamab treatment and explore their association with the incidence and severity of CRS.

II. To characterize peripheral T-cell subsets and activation states and explore phenotypic profiles associated with CRS.

OUTLINE:

Participants will receive epcoritamab combined with R-CHOP chemotherapy and dexamethasone. The treatment will be delivered in up to 8 cycles in an outpatient setting. participants are followed at Week 8 and every 3 months for up to one year, or until improvement or stabilization, or until new therapy begins, whichever occurs first.

03

Conditions studied

  • Non-Hodgkin's B-cell Lymphoma
  • Lymphoma Non-Hodgkin
  • Diffuse Large B-Cell Lymphoma (DLBCL)

Browse trials for

Keywords

  • Newly diagnosed B-cell lymphoma patients
  • Combination immunotherapy chemotherapy
  • epcoritamab R-CHOP lymphoma trial
04

In context

Lymphoma, Large B-Cell, Diffuse Reclassified

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

This study's planned enrollment of 20 is below the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Lead sponsor

This is the only study on the registry with Carrie Ho, MD as lead sponsor.

Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, B-Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must have confirmed CD20-positive aggressive B-cell lymphoma, including de novo or transformed diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS); high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement; primary mediastinal large B-cell lymphoma (PMBCL); T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL); Epstein-Barr virus-positive DLBCL, NOS; or follicular lymphoma grade 3b.
  2. per Lugano 2014 criteria.
  3. No prior therapy for DLBCL or FL G3B other than or palliative radiotherapy. Of note, a cycle of anthracycline-containing regimen (given as standard of care prior to study enrollment) is allowed, provided that patients will receive a total of six cycles of chemotherapy as part of their treatment plan. Patients who received one cycle of an anthracycline-containing regimen prior to enrollment will proceed directly to Cycle 2 on study.
  4. Age ≥18 years
  5. Participants must have an International Prognostic Index (IPI) score of 2-5.
  6. (ECOG) performance status ≤ 2 ( ≥ 60%)
  7. Demonstrates adequate organ function as defined below:

    Adequate bone marrow function:

    • 1.0 × 10⁹/Litre (L) (with growth factor use allowed)
    • 75 × 10⁹/L

    Exceptions:

    Patients may be enrolled despite not meeting the thresholds above if either of the following applies, provided the Absolute Neutrophil Count (ANC) is ≥0.75 × 10⁹/L:

    1. The patient has received one prior cycle of chemotherapy off study, and cytopenias at Cycle 2, Day 1 of protocol therapy are believed to be due to recent chemotherapy, provided there is evidence of marrow recovery and no other .
    2. The patient has documented bone marrow involvement by lymphoma, and cytopenias are believed to be disease-related rather than indicative of poor marrow reserve or unrelated pathology. In such cases, enrollment is permitted at the discretion of the investigator if the patient is otherwise eligible and deemed safe to proceed.

    Adequate hepatic function:

    Total

    ≤2 × (ULN) (unless due to Gilbert's)

    (AST) Serum glutamic-oxaloacetic transaminase (SGOT)

    ≤3 × institutional upper limit of normal

    Alanine aminotransferase (ALT) Serum glutamic-pyruvic transaminase (SGPT)

    ≤3 × institutional upper limit of normal

    Adequate renal function:

    As assessed by estimated (eGFR)

    Coagulation:

    (PT) International Normalized Ratio (INR) and Activated partial thromboplastin time aPTT

    ≤1.5 × ULN, unless receiving anticoagulation therapy

  8. (LVEF) ≥50% by multigated acquisition (MUGA) or echocardiography at screening.
  9. Ability to understand and the willingness to sign a written document.
  10. . (HIV)-infected individuals are eligible if the following criteria are met:

    1. Serum HIV viral load is \< lower limit of detection (LLD) and controlled with antiretroviral therapy for at least 1 year prior to enrollment, with confirmatory testing at screening;
    2. ≥ 200 cells/microliter (μL) at screening;
    3. Subject is receiving antiretroviral regimens in accordance with current International Acquired Immunodeficiency Syndrome (AIDS) Society guidelines;
    4. No evidence of AIDS-defining illnesses (other than lymphoma diagnosis) or active opportunistic infections;
    5. Antiretroviral therapy does not interfere with study medications.
  11. For participants with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
  12. Individuals with a history of virus (HCV) infection must have been treated and cured. For individuals with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  13. Individuals with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial.
  14. The effects of epcoritamab on the developing human fetus are unknown. For this reason, and because bispecific antibodies may be teratogenic, women of and men must agree to use adequate (hormonal or barrier method of birth control, or abstinence). Woman with must agree to use adequate contraception during the trial, and for 12 months after the last administration of epcoritamab or according to the local prescribing information of the standard of care (SOC) regimens, whichever is the longest. Adequate contraception is defined as highly effective methods of contraception. Also refer to the local prescribing information for information regarding contraceptive requirements for the SOC regimens.
  15. A woman of childbearing potential must have a negative serum (beta-hCG) pregnancy test at screening and a negative urine pregnancy test before treatment administration on Day 1 of every cycle.
  16. A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the trial and for 12 months after receiving the last dose of epcoritamab or according to the local prescribing information of the SOC regimens, whichever is the longest.
  17. A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control, eg, either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the trial and for 12 months after receiving the last dose of epcoritamab or according to the local prescribing information of the SoC regimens, whichever is the longest.
  18. Participants must agree not to donate blood for 60 days after receiving the last dose of trial treatment.
  19. Participants must have a treating physician at University of California, San Francisco (UCSF) or Zuckerberg San Francisco General Hospital (ZSFGH), receive study treatment under the supervision of the study Principal Investigator or qualified study sub-investigators at the enrolling site, and be willing to comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  1. History of severe allergic or anaphylactic reactions to anti-CD20 mAb therapy or known allergy or intolerance to any component or of epcoritamab.
  2. Any prior treatment with a bispecific antibody targeting CD3 and CD20.
  3. Treatment with an drug within 4 weeks or 5 half-lives, whichever is longer, prior to the first dose of epcoritamab.
  4. Requiring therapy for an ongoing baseline medical condition. For , prednisolone >10 mg daily (or equivalent) qualifies as immunosuppressive and thus be excluded for this use. Note: corticosteroids at any dose are permitted for control of lymphoma related symptoms, including during screening, and for any adverse events (AE) management during study.
  5. Vaccination with within 28 days prior to the first dose of epcoritamab.
  6. cardiovascular disease, including:

    1. Myocardial infarction within 6 months prior to the first dose of epcoritamab, or unstable or uncontrolled disease/condition related to or affecting cardiac function (eg, unstable angina, congestive heart failure Class III-IV), cardiac arrhythmia (NCI (CTCAE) Version 5 Grade 3 or higher), or clinically significant (ECG) abnormalities
    2. Screening 12-lead ECG showing a baseline Corrected for Heart Rate using Fridericia's Formula (QTcF) >470 msec
    3. Stroke within 6 months prior to first epcoritamab dose
  7. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at trial enrolment or significant infections within 2 weeks prior to the first dose of epcoritamab.
  8. Active Virus (HBV) (Deoxyribonucleic Acid Polymerase Chain Reaction (DNA PCR) -positive) or (Ribonucleic Acid Polymerase Chain Reaction (RNA PCR) -positive infection). Subjects with evidence of prior HBV but who are PCR-negative are permitted in the trial but should receive prophylactic antiviral therapy. Subjects who received treatment for Hepatitis C Virus (HCV) that was intended to eradicate the virus may participate if hepatitis C Ribonucleic acid (RNA) levels are undetectable.
  9. Known past or current other than inclusion diagnosis, except for:

    1. Cervical carcinoma of Stage 1B or less
    2. Non-invasive basal cell or squamous cell skin carcinoma
    3. Non-invasive, superficial bladder cancer
    4. Prostate cancer with a current Prostate-Specific Antigen (PSA) level \< 0.1 ng/milliliter (mL)
    5. Any curable cancer with a complete response (CR) of > 2 years duration.
  10. Neuropathy > grade 1 with the exception of neuropathy directly related to lymphoma (e.g., direct nerve compression from tumor).
  11. . Female who is pregnant, breast-feeding, or planning to become pregnant while enrolled in this trial or within 12 months after the last dose of epcoritamab; female subjects must also agree not to breastfeed during the entire trial and until 12 months after the last administration of study drug.
  12. Male who plans to father a child while enrolled in this trial or within 12 months after the last dose of epcoritamab.
  13. to any of the individual drugs of the R-CHOP regimen.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Arm A: Treatment with Standard Dexamethasone (First 6 participants)

    Participants will receive 8 cycles of rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, prednisolone (R-CHOP) chemotherapy combined with epcoritamab. A standard dose of dexamethasone is given in Cycle 2. Treatment includes six 21-day cycles: Cycle 1 consists of R-CHOP alone; Cycles 2-5 include R-CHOP on Day 1 with epcoritamab on Days 1, 8, and 15. In Cycle 2, dexamethasone is given on epcoritamab treatment days and for 3 subsequent days. In Cycle 6, both R-CHOP and epcoritamab are given on Day 1 only. This is followed by two 28-day consolidation cycles (Cycles 7-8) with epcoritamab on Day 1. Safety follow-up occurs at Week 8 and every 3 months for up to one year. Participants who discontinue due to adverse events will be followed until improvement or stabilization, or until new therapy begins, whichever occurs first.

    Drug: Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP) · Drug: Epcoritamab · Drug: Dexamethasone · Procedure: Positron Emission Tomography (PET) · Procedure: Blood specimen collection · Behavioral: Questionnaires · Procedure: Computerized tomography (CT)

  • Experimental
    Arm B: Treatment with Modified Dexamethasone

    Participants will receive 8 cycles of rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, prednisolone (R-CHOP) chemotherapy combined with epcoritamab. A modified dose of dexamethasone will be given in Cycle 2. Treatment includes six 21-day cycles: Cycle 1 consists of R-CHOP alone; Cycles 2-5 include R-CHOP on Day 1 with epcoritamab on Days 1, 8, and 15. In Cycle 2, dexamethasone is administered on epcoritamab treatment days and the following day. In Cycle 6, both R-CHOP and epcoritamab are given on Day 1 only. This is followed by two 28-day consolidation cycles (Cycles 7-8) with epcoritamab on Day 1. Safety follow-up occurs at Week 8 and every 3 months for up to one year. Participants who discontinue due to adverse events will be followed until improvement or stabilization, or until new therapy begins, whichever occurs first.

    Drug: Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP) · Drug: Epcoritamab · Drug: Dexamethasone · Procedure: Positron Emission Tomography (PET) · Procedure: Blood specimen collection · Behavioral: Questionnaires · Procedure: Computerized tomography (CT)

Interventions

  • DrugRituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP)

    Given orally and intravenously (IV)

    Also known as: R-CHOP-21

  • Given subcutaneously (SC)

    Also known as: EPKINLY, epcoritamab-bysp

  • Given orally

  • ProcedurePositron Emission Tomography (PET)

    Undergo imaging

  • ProcedureBlood specimen collection

    Perform Blood work

  • BehavioralQuestionnaires

    Participants complete European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)

  • ProcedureComputerized tomography (CT)

    Undergo Imaging

07

What researchers measure

Primary outcomes

  1. Cytokine Release Syndrome (CRS) Rate

    The cytokine release syndrome (CRS) rate is defined as the incidence of CRS of any grade during Cycle 2, graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) consensus criteria. The proportion and corresponding 95% confidence interval will be reported.

    Time frame: Up to day 42

Secondary outcomes

  1. Proportion of Participants with Treatment-emergent Adverse Events

    Proportion of participants with treatment-emergent adverse events, classified according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0. The proportion and 95% confidence interval will be reported.

    Time frame: Up to 60 days after treatment

  2. Overall Response (OR)

    Overall response (OR) is defined as the proportion of treated participants who obtained an radiographic objective response confirmed complete response (CR) or confirmed partial response (PR) per Lugano Classification. The proportion and 95% confidence interval will be reported.

    Time frame: Up to 2 years

  3. Duration of Overall Response

    Duration of overall response is defined as the time from first documentation of complete response (CR) or partial response (PR) to the first occurrence of disease progression, recurrence, or death, whichever occurs first. Patients without progression who are alive at the clinical cutoff will be censored at the date of their last disease assessment. Median, estimates and 95% confidence interval will be reported using the Kaplan-Meier method and Brookmeyer and Crowley method.

    Time frame: Up to 2 years

  4. Median Progression-Free Survival (PFS)

    Progression-free survival (PFS) is the time from the first dose of treatment until disease progression or death, whichever occurs first. If neither event occurs, PFS is measured up to the last adequate disease assessment. If a patient is alive but has no tumor assessments after starting treatment, PFS is measured up to the first dose date. Median, estimates and 95% confidence interval will be reported using the Kaplan-Meier method and Brookmeyer and Crowley method.

    Time frame: Up to 2 years

  5. Median Overall Survival (OS)

    Overall survival (OS) is the time from the first dose of treatment until death from any cause. Patients who are still alive will be followed up to their last known contact date. Median, estimates and 95% confidence interval will be reported using the Kaplan-Meier method and Brookmeyer and Crowley method.

    Time frame: Up to 2 years.

08

Study locations

2 sites
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2028, 21 months later.

Of 210 non-industry phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 21 months is below that.

Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 15, 2026
StartEst.
Nov 15, 2026was Sep 2026
Primary completionEst.
Aug 31, 2028
CompletionEst.
Aug 31, 2029
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 15, 2026→Nov 15, 2026
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Start date Sep 15, 2026→Nov 15, 2026
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07588698
Lead sponsor
Carrie Ho, MD
Responsible party
Carrie Ho, MD (Principal investigator, University of California, San Francisco) — Sponsor-investigator
First posted
May 15, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
Aug 31, 2028 (estimated)
Completion
Aug 31, 2029 (estimated)
Last update
Oct 1, 2026

Study contacts

UCSF Hematopoietic Malignancies Clinical Trial Recruitment
Contact
HDFCCC.Heme@ucsf.edu
877-827-3222
Clinical Trial Recruitment
Contact
cancertrials@ucsf.edu
Carrie Ho, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epcoritamab

Start the discussion